drugset / Trial / NCT07476378
A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies
Not yet recruiting
69 enrolled
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
MagicTime Medicine · collab
NaSequentialOpen-labelTreatment
Summary
This is an investigator-initiated, open-label, single-arm, dose-escalation and dose-expansion study to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of MTM-H-001 in adult participants with relapsed/refractory (R/R) B-cell malignancies.
Timeline
- Start
- 2026-03
- Primary completion
- 2028-01
- Completion
- 2028-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MTM-H-001 | Unknown | — | — |